SITE004-0017

SITE004 (DEU) › SITE004-0017

SITE004-0017

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2025-09-07

enrolled

AEs

4

Serious

1

Dropout signal

–

Adverse events

4

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 162); relationship: not assessed

moderate assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-28 (study day 128); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 39); relationship: NOT RELATED

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-23 (study day 32); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.